Impact of refitted race-free eGFR formula on obesity pharmacotherapy options.
Babak J OrandiChandler McLeodRhiannon D ReedVineeta KumarLeon I IgelLouis J AronneRobert M CannonCora Elizabeth LewisJayme E LockePublished in: Obesity (Silver Spring, Md.) (2022)
These findings highlight the importance of measuring-rather than estimating-GFR in Black people with CKD when considering many antiobesity pharmacotherapy options.